000164145 001__ 164145
000164145 005__ 20231219114224.0
000164145 0247_ $$2doi$$a10.1007/s00115-021-01077-1
000164145 0247_ $$2pmid$$apmid:33651117
000164145 0247_ $$2pmc$$apmc:PMC7923405
000164145 0247_ $$2ISSN$$a0028-2804
000164145 0247_ $$2ISSN$$a1433-0407
000164145 0247_ $$2altmetric$$aaltmetric:101194268
000164145 037__ $$aDZNE-2022-00801
000164145 041__ $$aGerman
000164145 082__ $$a610
000164145 1001_ $$aSkripuletz, Thomas$$b0
000164145 245__ $$aNeuroimmunologie von COVID‑19.
000164145 260__ $$aHeidelberg$$bSpringer$$c2021
000164145 3367_ $$2DRIVER$$aarticle
000164145 3367_ $$2DataCite$$aOutput Types/Journal article
000164145 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1702906716_15628
000164145 3367_ $$2BibTeX$$aARTICLE
000164145 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000164145 3367_ $$00$$2EndNote$$aJournal Article
000164145 520__ $$aMany neuroimmunological diseases, such as encephalopathy, encephalitis, myelitis and acute disseminated encephalomyelitis (ADEM) have occurred more frequently after infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which indicates a parainfectious or postinfectious association. The most likely underlying mechanisms include virus-triggered overactivation of the immune system with hyperinflammation and cytokine storm but potentially also the development of specific autoantibodies against central nervous system (CNS) tissue. These were predominantly detected in the cerebrospinal fluid of severely ill coronavirus disease 2019 (COVID-19) patients. In contrast, direct damage after invasion of SARS-CoV‑2 into the brain and spinal cord does not seem to play a relevant role. Susceptibility to infection with SARS-CoV‑2 in patients with multiple sclerosis, myasthenia or other neuroimmunological diseases including the risk for severe disease courses, is not determined by the administered immunotherapy but by known risk factors, such as age, comorbidities and the disease-related degree of disability. Therefore, immunotherapy in these patients should not be delayed or discontinued. The contribution of neuroimmunological mechanisms to long-term sequelae after survival of a COVID-19 illness, such as fatigue, impairment of memory, sleep dysfunction or anxiety, will require long-term clinical follow-up, preferentially in COVID-19 register studies.
000164145 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000164145 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000164145 650_7 $$2Other$$aAutoantibodies
000164145 650_7 $$2Other$$aEncephalitis
000164145 650_7 $$2Other$$aHyperinflammation
000164145 650_7 $$2Other$$aImmunotherapy
000164145 650_7 $$2Other$$aMyelitis
000164145 650_2 $$2MeSH$$aBrain Diseases
000164145 650_2 $$2MeSH$$aCOVID-19
000164145 650_2 $$2MeSH$$aEncephalitis
000164145 650_2 $$2MeSH$$aHumans
000164145 650_2 $$2MeSH$$aNeuroimmunomodulation
000164145 650_2 $$2MeSH$$aSARS-CoV-2
000164145 7001_ $$aMöhn, Nora$$b1
000164145 7001_ $$0P:(DE-2719)2811159$$aFranke, Christiana$$b2$$udzne
000164145 7001_ $$0P:(DE-2719)2810931$$aPrüß, Harald$$b3$$eLast author$$udzne
000164145 773__ $$0PERI:(DE-600)1462945-8$$a10.1007/s00115-021-01077-1$$gVol. 92, no. 6, p. 521 - 530$$n6$$p521 - 530$$tDer Nervenarzt$$v92$$x0028-2804$$y2021
000164145 8564_ $$uhttps://pub.dzne.de/record/164145/files/DZNE-2022-00801.pdf$$yOpenAccess
000164145 8564_ $$uhttps://pub.dzne.de/record/164145/files/DZNE-2022-00801.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000164145 909CO $$ooai:pub.dzne.de:164145$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000164145 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2811159$$aExternal Institute$$b2$$kExtern
000164145 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810931$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000164145 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000164145 9141_ $$y2021
000164145 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000164145 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-12
000164145 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-28
000164145 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-12
000164145 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-28
000164145 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-12
000164145 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNERVENARZT : 2021$$d2022-11-12
000164145 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-28
000164145 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2021-01-28$$wger
000164145 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-12
000164145 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2022-11-12
000164145 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000164145 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-12
000164145 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-12
000164145 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-12
000164145 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-12
000164145 9201_ $$0I:(DE-2719)1810003$$kAG Prüß$$lAutoimmune Encephalopathies$$x0
000164145 980__ $$ajournal
000164145 980__ $$aVDB
000164145 980__ $$aUNRESTRICTED
000164145 980__ $$aI:(DE-2719)1810003
000164145 9801_ $$aFullTexts